Cardiovascular disease is still one of the biggest health challenges of our time. Through excellent science, innovation and effective organisation of care, we have been able to successfully combat acute cardiovascular events; we have saved many lives. This has however led to an increase in the number of chronic patients. Together with the best Dutch scientists, leading organisations representing patients, academia, healthcare professionals, industry and government have joined forces to establish the Dutch CardioVascular Alliance. The alliance works on the following five priorities: research policy designed to maximise impact, fast tracks from idea to company and from lab to patient, career perspectives for research talents and improve data infrastructure. Together we share the ambition to lower the cardiovascular disease burden by 25% in 2030 by earlier recognition of disease and rapid translation of excellent science into health improvement.
The NVVC (Netherlands Society of Cardiologie) connects cardiologists and other health care professionals which are involved in the treatment of patients with cardiovascular diseases. The mission of the NVVC is to contribute to the provision and development of high quality cardiovascular care in the Netherlands.
WCN (Dutch Network for Cardiovascular Research) is a research network of almost 60 cardiovascular institutes within the Netherlands. We partner with pharmaceutical companies, contract research organizations (CRO) and academic research organizations (ARO) from trial design to publication. Our network members are experienced professionals with excellent knowledge of clinical research. Together with qualified research professionals and dedicated staff, WCN ensures quality in clinical research. From start to finish, we maintain a reliable association throughout the collaboration.
Durrer Center for Cardiovascular Research is initiated by the Netherlands Heart Institute (NL-HI) in 2008. The Netherlands Heart Institute fosters excellent cardiovascular research on national and international level. NL-HI conducts basic science as well as clinical research. NL-HI aims to promote cooperations between university medical centers (UMC’s) in the Netherlands and between scientists and the private sector. Durrer Center facilitates high-quality logistic support in collection and storage of sample and data for researchers in the field of cardiovascular research. Providing a transparent mechanism for sample and data access will benefit the entire scientific community and society. The main principle is that biomaterials and research data are Findable (F), Interoperable (I), Accessible (A) and Reusable (R). Durrer Center has a neutral and independent position in relation to the individual UMC’s, researchers/consortia and other parties.
The Netherlands Heart Registration (NHR) aims to improve the quality of cardiovascular healthcare in the Netherlands by creating transparency on patient-relevant outcomes. It collects and analyzes data from all cardiovascular interventions and surgeries in the Netherlands, for example cardiothoracic surgery, PCI’s, TAVI’s, PM and ICD implantations and ablations. In addition to these intervention-based registries, data is also collected for specific cardiovascular conditions such as atrial fibrillation and heart failure.
The NHR processes data on behalf of all Dutch hospitals, and facilitates the use of their data for scientific research and innovation projects. The NHR is a NEN-certified organization and is compliant with GDPR legislation.
In total, the NHR collects data from over 80.000 interventions and surgeries annually.
The Dutch Heart Foundation (DHF) is a Netherlands-based charity that aims to reduce the burden caused by cardiovascular diseases and keep hearts healthy through stimulating (collaborations in) cardiovascular research and enhancing knowledge and awareness on these devestating diseases. The DHF works together with scientists, physicians, patients, public and private organisations and many volunteers on solutions for the early detection of cardiovascular diseases and better treatments for these diseases. The DHF stimulates research and innovation and provides support and information to (at-risk) patients.
Harteraad is the center of expertise for living with cardiovascular diseases. We help people and their loved ones by offering practical, social and emotional support. Working together with highly experienced volunteers throughout the Netherlands, Harteraad offers a safe place for the exchange of knowledge, encounters, and experiences. Our goal is that you can live your life as fully as possible, despite your condition. Hearteraad advocates the interests of more than 1.5 million people with cardiovascular disease. Because of the knowledge and experiences of these people, Harteraad understands what they are going through and what they need. Harteraad is then able to represent them to the government, scientific researchers, insurers, and healthcare professionals.
is a British Heart Foundation (BHF) COVID-19 Cardiovascular Disease UK flagship project. It is led by Professor Bryan Williams, Director of the NIHR University College Hospitals Biomedical Research Centre (BRC), with strong regional support. The BRC Clinical and Research Informatics Unit (CRIU) provides the data hosting infrastructure by establishing a local REDCap instance and server and coordinating data collection and transfer from participating sites, including outputs from the ISARIC-WHO REDCap uploads where applicable. REDCap, the Clinical Data Entry tool supporting the project, is hosted by AIMES Management Services Ltd.
BHF funds over £100 million of research each year into all heart and circulatory diseases and the risk factors that cause them. Conditions such as myocardial infarction, stroke, vascular dementia and diabetes are all linked and BHF research aims to unlock the connections between heart and circulatory diseases and their risk factors.
NIHR is the UK’s largest funder of health and care research and provides the people, facilities and technology that enable research to thrive. Working in partnership with the NHS, universities, local government, other research funders, patients and the public, NIHR delivers and enables world-class research that transforms people’s lives, promotes economic growth and advances science. NIHR is primarily funded by the Department of Health and Social Care, but also receive UK Aid funding to support research for people in low- and middle-income countries.
The NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London is the result of an outstanding partnership between University College London Hospitals NHS Foundation Trust (UCLH) and UCL. The BRC supports experimental medicine research at UCLH and UCL. It does this by investing in staff posts, equipment, facilities and training. The aim is to turn innovations in basic science into treatments and therapies that have a direct effect on patients.
UCLH provides first-class acute and specialist services in six hospitals in central London.
• University College Hospital (incorporating the Elizabeth Garrett Anderson Wing, the Macmillan Cancer Centre and University College Hospital at Westmoreland Street)
• Royal London Hospital for Integrated Medicine
• Royal National ENT and Eastman Dental Hospitals
• National Hospital for Neurology and Neurosurgery at Queen Square, Cleveland Street and Chalfont
• Institute of Sport, Exercise and Health
• Hospital for Tropical Diseases
UCLH’s mission is to deliver top-quality patient care, excellent education and world-class research.
In partnership with University College London (UCL) UCLH is one of the UK’s five comprehensive biomedical research centres.
Founded in 1826 in the heart of London, UCL is London’s leading multidisciplinary university, with more than 13,000 staff and 42,000 students from 150 different countries.
Through a progressive approach to teaching and research, world leading academics, curious students and outstanding staff continually pursue excellence, break boundaries and make an impact on real world problems.
Contact the UK team at: firstname.lastname@example.org
Will follow soon.